Compositions comprising cannabinoids and methods of use thereof
AssigneeSchedule 1 Therapeutics, Inc.
InventorGeorge D. Pappas
Life of this patent
Estimating the term…
Abstract
The present disclosure is related to the use of compositions and their use in reducing pain.
Claims8
A method of reducing acute migraine pain, photophobia, phonophobia, nausea, or frequency in a subject, the method comprising administering a pharmaceutically effective amount of at least one minor cannabinoid in combination with THC and CBD such that at least one biomarker of central and peripheral sensitization is modulated and acute migraine pain, photophobia, phonophobia, nausea, or frequency is reduced in the subject, wherein the composition comprises 80 w/w % CBD to 99.9 w/w % CBD and 0.1 w/w % THC to 20 w/w % THC wherein the biomarker is selected from the group consisting of NMDA, glutamate, CGRP, FAAH, Substance P, NO, GABA, NGF, serotonin, dopamine, AEA, and 2-AG.
A method of reducing acute migraine pain, photophobia, phonophobia, nausea, or frequency in a subject, the method comprising administering a pharmaceutically effective amount of at least one minor cannabinoid in combination with THC and CBD such that at least one biomarker of central and peripheral sensitization is modulated and acute migraine pain, photophobia, phonophobia, nausea, or frequency is reduced in the subject, wherein the composition comprises at least 90 w/w % CBD and no more than 10 w/w % THC wherein the biomarker is selected from the group consisting of NMDA, glutamate, CGRP, FAAH, Substance P, NO, GABA, NGF, serotonin, dopamine, AEA, and 2-AG.
Dependencies are inferred from the claim text.